Gilead reports positive data from four Phase III combination trials for HIV-1

US-based biopharmaceutical firm Gilead Sciences has reported positive results from four Phase III clinical trials investigating the combination of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) to treat patients with HIV-1.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news